Natalie A Drucker1, Jan P Te Winkel2, W Christopher Shelley3, Kenneth R Olson4, Troy A Markel2. 1. Department of Surgery, Section of Pediatric Surgery, Riley Hospital for Children at Indiana University Health, Indianapolis, IN; The Indiana University School of Medicine, Indianapolis, Indianapolis, IN. Electronic address: ndrucker@iupui.edu. 2. Department of Surgery, Section of Pediatric Surgery, Riley Hospital for Children at Indiana University Health, Indianapolis, IN; The Indiana University School of Medicine, Indianapolis, Indianapolis, IN. 3. Department of Surgery, Section of Pediatric Surgery, Riley Hospital for Children at Indiana University Health, Indianapolis, IN. 4. The Indiana University School of Medicine, South Bend, South Bend, IN.
Abstract
INTRODUCTION: Umbilical mesenchymal stem cells (USC) have been shown to reduce illness in animal models of necrotizing enterocolitis (NEC), possibly through the paracrine release of hydrogen sulfide (H2S). We hypothesized that animals treated with USCs with inhibited H2S synthesis would exhibit more severe disease. METHODS: NEC was induced in five-day-old mouse pups by formula feeding and hypoxic and hypothermic stress. Experimental groups received intraperitoneal injection of either saline vehicle or 80,000cells/gram of one of the following cell types: USC, USCs with negative-control siRNA, or USCs with targeted siRNA inhibition of the H2S-producing enzymes. Pups were monitored by clinical assessment and after euthanasia, intestine and lung histologic injury were scored. Tissue was homogenized, and concentrations of IL-6, IL-10, and VEGF were determined by ELISA. For statistical analysis, p<0.05 was considered significant. RESULTS: Animals treated with negative-control siRNA USCs were significantly improved compared to vehicle. Clinical sickness scores as well as intestinal and lung histologic injury scores in the targeted siRNA groups were significantly worse when compared to the negative-control siRNA group. IL-6, IL-10, and VEGF had varying patterns of expression in the different groups. CONCLUSION: Inhibition of H2S production in USCs reduces the beneficial effects of these cells during therapy in experimental NEC. LEVEL OF EVIDENCE: Animal studies are typically described as "foundational evidence" without a true level assigned. TYPE OF STUDY: Animal Study.
INTRODUCTION: Umbilical mesenchymal stem cells (USC) have been shown to reduce illness in animal models of necrotizing enterocolitis (NEC), possibly through the paracrine release of hydrogen sulfide (H2S). We hypothesized that animals treated with USCs with inhibited H2S synthesis would exhibit more severe disease. METHODS: NEC was induced in five-day-old mouse pups by formula feeding and hypoxic and hypothermic stress. Experimental groups received intraperitoneal injection of either saline vehicle or 80,000cells/gram of one of the following cell types: USC, USCs with negative-control siRNA, or USCs with targeted siRNA inhibition of the H2S-producing enzymes. Pups were monitored by clinical assessment and after euthanasia, intestine and lung histologic injury were scored. Tissue was homogenized, and concentrations of IL-6, IL-10, and VEGF were determined by ELISA. For statistical analysis, p<0.05 was considered significant. RESULTS: Animals treated with negative-control siRNA USCs were significantly improved compared to vehicle. Clinical sickness scores as well as intestinal and lung histologic injury scores in the targeted siRNA groups were significantly worse when compared to the negative-control siRNA group. IL-6, IL-10, and VEGF had varying patterns of expression in the different groups. CONCLUSION: Inhibition of H2S production in USCs reduces the beneficial effects of these cells during therapy in experimental NEC. LEVEL OF EVIDENCE: Animal studies are typically described as "foundational evidence" without a true level assigned. TYPE OF STUDY: Animal Study.
Authors: Neel R Sodha; Richard T Clements; Jun Feng; Yuhong Liu; Cesario Bianchi; Eszter M Horvath; Csaba Szabo; Gregory L Stahl; Frank W Sellke Journal: J Thorac Cardiovasc Surg Date: 2009-06-13 Impact factor: 5.209
Authors: Tamas Jilling; Dyan Simon; Jing Lu; Fan Jing Meng; Dan Li; Robert Schy; Richard B Thomson; Antoine Soliman; Moshe Arditi; Michael S Caplan Journal: J Immunol Date: 2006-09-01 Impact factor: 5.422
Authors: Cüneyt Tayman; Duygu Uckan; Emine Kilic; Ahmet Tulga Ulus; Alparslan Tonbul; Ibrahim Murat Hirfanoglu; Fatma Helvacioglu; Hacer Haltas; Burhan Koseoglu; M Mansur Tatli Journal: Pediatr Res Date: 2011-11 Impact factor: 3.756
Authors: Carolina Allers; Walter D Sierralta; Sonia Neubauer; Francisco Rivera; José J Minguell; Paulette A Conget Journal: Transplantation Date: 2004-08-27 Impact factor: 4.939
Authors: Jan Te Winkel; Quincy E John; Brian D Hosfield; Natalie A Drucker; Amitava Das; Ken R Olson; Troy A Markel Journal: Am J Physiol Gastrointest Liver Physiol Date: 2019-07-25 Impact factor: 4.052